Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.

Jin ZhaoLihong LiuHao LiDan SunYi HuChen ZhangYuhui Zhang

Published in: Expert opinion on drug safety (2023)

ALK-TKIs were associated with higher risks of cardiovascular toxicities. Special attention should be given to the risks of cardiac disorders and VTEs related to crizotinib therapy.

Keyphrases

human health
advanced non small cell lung cancer
risk assessment
double blind
open label
working memory
left ventricular
randomized controlled trial
heart failure
climate change
phase ii
drug induced